查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2056624

血友病市場規模、佔有率、趨勢和預測：按治療方法、療法和地區分類，2026-2034 年

Hemophilia Market Size, Share, Trends and Forecast by Type, Treatment, Therapy, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3個工作天內

價格

2025年全球血友病市場規模為157億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以9.0%的複合年成長率成長，到2034年達到348億美元。目前，北美市場佔據主導地位，預計2025年市佔率將超過49.7%。市場擴張主要得益於基因療法和長效治療方法的投資不斷增加。同時，患者意識的提高和個人化醫療的進步也持續推動著市場發展，進一步鞏固了已開發地區和新興地區血友病市場的佔有率。

由於研發領域的巨額投資，該市場已發生顯著變化。這些資金推動了基因療法等創新治療方法的開發，並有望為患者提供長期解決方案。隨著全球血友病病例的增加，人們正努力改進治療方法，以減少因子替代療法的頻率。半衰期長的治療方法就是一個例子，它們透過減少靜脈輸注的頻率，切實提高了患者的生活品質。另一方面，個人化治療方法，從而確保治療方案能更好地滿足每位患者的特定需求。在美國，對先進血友病療法的需求正在穩步成長，這主要源於人們對更有效、更簡單的治療方法的渴望。

隨著血友病患者人數的不斷增加，人們越來越關注治療方法。基因療法作為一種潛在的長期或永久性治療方案，正受到廣泛關注，目前日本正在進行多項臨床試驗。美國政府和醫療機構也越來越重視擴大這些新治療方法的覆蓋範圍，並致力於提高其可近性和可負擔性。這一點尤其重要，因為患者正在尋求替代傳統凝血因子替代療法（需要定期輸液）的方案。此外，新型凝血因子濃縮物和非因子療法的核准為患者提供了更好的治療選擇，有助於減少出血事件和住院次數。

血友病市場趨勢：

血友病患者人數不斷增加以及治療的進步

全球血友病及相關遺傳疾病盛行率的不斷上升是推動全球血友病市場成長的主要促進因素。 2023年，全球約有21.9萬人被診斷為血友病。診斷病例的增加以及預防性療法的廣泛應用，為市場成長提供了巨大的機會。此外，各國政府機構正在進行宣傳宣傳活動，提高人們對早期診斷和新生兒篩檢重要性的認知，這也有助於提升該產業的良好發展前景。同時，有限的治療選擇也促使研發投入不斷增加。該領域的領導者正致力於開發先進的診斷工具和治療方法，旨在提高治療的有效性和準確性，從而增強市場潛力。此外，全球正在大力投資建立專業的血友病治療中心（HTC），預計這將進一步推動市場成長。例如，2023年，HTC資助計畫支持了12個國家的20個中心，有助於加強資料收集和改善患者照護。

血友病基因治療的進展

隨著創新治療方法的湧現，全球血友病市場正經歷一場重大變革，以因應長期存在的治療難題。傳統的治療方法，例如頻繁的凝血因子替代療法，往往成本高且患者依從性差。這導致人們對替代療法的需求日益成長，這些療法不僅能夠改善患者的治療效果，還能提供長期的解決方案。基因療法的興起是最具前景的進展之一，它有望消除定期輸血的必要性，並為全球血友病患者提供永續的治療模式。例如，2024年12月，印度成功實施了首例使用慢病毒載體治療重度A型血友病的人類基因療法。這項突破性的治療實現了零出血，並展現出長期的止血保護作用。此外，該治療方法還消除了反覆輸血的需求，減輕了患者的經濟和身體負擔。這項成功凸顯了基因療法在血友病市場的未來潛力，使其成為改變我們治療方式的強大選擇。隨著基因療法的日益普及，預計將透過為全球血友病患者提供創新、經濟高效且長期有效的解決方案，大幅擴大市場規模。這一轉變很可能與血友病市場對先進且永續治療方法的日益成長的需求相契合。

血友病治療的便利性與個人化

隨著全球血友病市場的持續成長，人們對更便利、更個人化的治療方法的需求日益成長。目前許多治療方法，尤其是靜脈輸注，耗時費力，需要頻繁就醫，造成病人許多不便。隨著以患者為中心的護理理念日益重要，人們對能夠透過簡單給藥和個人化治療方案來提高生活品質的治療方法的需求也日益成長。這推動了更容易取得、更人性化的治療方法的研發，進一步加速了血友病市場的創新。例如，2025年1月，FDA核准了concisumab-mtci（Alhemo），這是第一個用於治療A型和B型血友病伴抑制因子的皮下預防性療法。基於3期臨床試驗數據，此突破性治療方法透過皮下注射，無需靜脈輸注，為患者提供了更方便的選擇。 「Alhemo」的核准對存在抑制因子的患者而言意義重大，它為現有治療方法提供了一種期待已久的替代方案，並提高了血友病治療的柔軟性和便利性。這項新核准正推動血友病市場轉向更有效、更個人化的治療方法，以滿足患者的個別需求，進而改善治療的可及性。因此，市場正在迅速擴張，為滿足全球血友病患者的多樣化需求，提供更多個人化照護解決方案的機會。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球血友病市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依類型

  • A型血友病
  • B型血友病
  • C型血友病
  • 其他

第7章 市場區隔：依治療方式分類

  • 一經請求
  • 預防

第8章 市場區隔：依療法分類

  • 替代療法
  • ITI療法
  • 基因治療

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Baxter International Inc.
    • Bayer AG
    • BioMarin Pharmaceutical Inc.
    • CSL Behring（CSL Limited）
    • F. Hoffmann-La Roche AG
    • Grifols SA
    • Kedrion SpA
    • Novo Nordisk A/S
    • Octapharma AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
Product Code: SR112026A4508

The global hemophilia market size was valued at USD 15.7 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 34.8 Billion by 2034, exhibiting a CAGR of 9.0% during 2026-2034. North America currently dominates the market, holding a significant market share of over 49.7% in 2025.The market is expanding due to increased investment in innovative therapies, including gene therapy and treatments with extended half-lives. At the same time, rising patient awareness and advancements in personalized medicine continue to drive the market, further supporting the hemophilia market share in both developed and emerging regions.

The market has undergone tremendous evolution on account of being subject to high R&D spending. The funding bestowed innovations in therapies such as gene therapies which purport to give solutions that would last such patients. Efforts have gone into enhancing treatments in an attempt to cut down factor replacement therapy rate as hemophilia cases are on the rise globally. With longer half-life treatment being one such treatment, in fact, it decreases the infusion rate for the patients to elevate their quality of life. Another aspect has been the personalized treatment methods that have been under development with growing inclination toward personalized medicine, ensuring that treatment cater more toward the particular needs of an individual patient. In the U.S., demand for advanced hemophilia treatment has picked up well, driven largely by the demand for better and easy methods of treatments.

As the population of individuals with hemophilia increases, there is a rising focus on therapies that offer improved efficacy and fewer infusions, ultimately enhancing patients' quality of life. Gene therapies, which offer the potential for long-term or permanent treatment solutions, have garnered significant attention, with several clinical trials underway in the country. The US government and healthcare centers have also expressed greater interest in opening up access to these new treatments, promoting treatments to become more accessible and affordable. This has been particularly significant as patients look for alternatives to conventional factor replacement treatments that take place regularly through infusions. Additionally, the approval of new clotting factor concentrates, and non-factor therapies has provided better management options for patients, allowing for fewer bleeding episodes and reducing the need for hospital visits.

Hemophilia Market Trends:

Increasing Hemophilia Cases and Advancements

The increasing worldwide incidence of hemophilia and genetic disorders are key drivers fuelling the global hemophilia market growth. In 2023, almost 219,000 individuals globally were diagnosed with hemophilia. The increasing number of diagnoses, combined with the growing adoption of prophylactic therapy, represents a huge opportunity for market growth. Additionally, various governmental bodies are conducting campaigns to raise awareness about the importance of early diagnosis and neonatal screening, which is fostering positive growth prospects for the industry. Furthermore, increased investment in research and development (R&D) is being driven by the limited treatment options available. Leading companies in the sector are focusing on developing advanced diagnostic tools and therapies that aim to improve treatment effectiveness and precision, boosting the market's potential. Moreover, substantial investments in the creation of specialized hemophilia treatment centers (HTCs) worldwide are expected to drive market growth further. For example, in 2023, the HTC Funding Program provided support to 20 centers across 12 countries, strengthening data collection and enhancing patient care.

Advancements in Gene Therapy for Hemophilia

The global hemophilia market is undergoing significant transformation as new and innovative therapies emerge to address longstanding challenges in treatment. Traditional approaches, such as frequent factor replacement infusions, often come with high costs and compliance issues for patients. This has led to an increasing demand for alternative therapies that not only improve patient outcomes but also provide long-term solutions. One of the most promising advancements is the rise of gene therapy, offering the potential to eliminate the need for regular infusions and provide a more sustainable treatment model for hemophilia patients worldwide. For instance, in December 2024, India's first human gene therapy for severe Hemophilia A was successfully conducted using a lentiviral vector. This groundbreaking treatment resulted in zero bleeding episodes, demonstrating its effectiveness in providing long-term protection against bleeding. The therapy also eliminated the need for repeated infusions, reducing both the cost and burden on patients. This success highlights the future potential of gene therapies in the hemophilia market, making them a strong contender in transforming the treatment landscape. As gene therapies gain traction, they are expected to significantly expand the market, offering an innovative, cost-effective, and long-term solution for hemophilia patients globally. With this shift, the hemophilia market trends are set to align with the growing demand for advanced, sustainable treatment options.

Convenience and Personalization in Hemophilia Treatments

As the global hemophilia market continues to grow, there is an increasing emphasis on treatments that offer greater convenience and personalization. Many current therapies, particularly intravenous infusions, are time-consuming, require frequent hospital visits, and can be inconvenient for patients. As patient-centric care becomes more important, the demand for therapies that improve quality of life through ease of administration and personalized treatment regimens is on the rise. This has spurred the development of more accessible and patient-friendly treatment options, further driving innovation in the hemophilia market. For instance, in January 2025, the FDA approved Concizumab-mtci (Alhemo), the first subcutaneous prophylactic treatment for Hemophilia A and B with inhibitors. This novel treatment, based on phase 3 clinical trial data, offers patients a more convenient option by providing a subcutaneous injection, eliminating the need for intravenous infusions. The approval of Alhemo is a game-changer for patients with inhibitors, providing a much-needed alternative to existing treatments and increasing the flexibility and convenience of managing hemophilia. With this new approval, the hemophilia market is witnessing a shift toward therapies that are not only more effective but also tailored to the individual needs of patients, making treatment more accessible. As a result, this market is expanding rapidly, with greater opportunities for personalized care solutions to address the diverse needs of hemophilia patients worldwide.

Hemophilia Industry Segmentation:

The publisher provides an analysis of the key trends in each segment of the global hemophilia market, along with forecasts at the global, regional, and country levels from 2026-2034. The market has been categorized based on type, treatment, and therapy.

Analysis by Type:

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Others

As per the hemophilia market outlook, in 2025, the hemophilia A segment led the market, accounting for 75.3% of the total market share driven by higher prevalence of Hemophilia A compared to Hemophilia B, with more patients diagnosed with Factor VIII deficiency. Additionally, advancements in therapies specifically targeting Hemophilia A, such as gene therapy and improved clotting factor products, have contributed to this growth. The increasing diagnosis rate and the popularity of prophylactic treatments that prevent bleeding episodes have also played a critical role in driving the demand for Hemophilia A treatments. With the continued focus on developing more effective, long-lasting therapies, the Hemophilia A segment is expected to maintain its leading position in the global market.

Analysis by Treatment:

  • On-Demand
  • Prophylaxis

In 2025, the on-demand segment led the hemophilia market, driven by the preference for immediate intervention to manage bleeding episodes. On-demand therapy is primarily used to treat spontaneous bleeds and trauma, offering patients quick access to treatment when needed. This segment has gained traction due to its flexible and responsive nature, particularly for patients who experience occasional bleeding episodes. Additionally, the development of more advanced and easier-to-administer on-demand treatments, such as subcutaneous injections and extended-acting factor therapies, has enhanced patient compliance and convenience. As these therapies continue to improve in terms of effectiveness and ease of use, the on-demand treatment segment remains a crucial player in the Hemophilia market.

Analysis by Therapy:

  • Replacement Therapy
  • ITI Therapy
  • Gene Therapy

In 2025, the replacement therapy segment led the hemophilia market, accounting for 61.7% of the total market share, driven by the effectiveness of replacement therapies in treating both Hemophilia A and B. These therapies involve replacing the missing clotting factors (Factor VIII for Hemophilia A and Factor IX for Hemophilia B), directly addressing the root cause of bleeding episodes. With continuous advancements in the half-life of clotting factors, extended-acting therapies have gained preference, providing longer protection against bleeding episodes and reducing the frequency of infusions. The widespread use of prophylactic replacement therapy has also contributed to the segment's leading position, as it helps patients maintain better overall health and quality of life.

Regional Analysis:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

In 2025, the North America segment led the hemophilia market, accounting for 49.7% of the total market share, driven by its high healthcare expenditure, advanced healthcare infrastructure, and extensive access to innovative therapies. North America also benefits from a well-established network of specialized hemophilia treatment centers (HTCs) and significant government support for healthcare research and development. Furthermore, the presence of leading pharmaceutical companies developing innovative hemophilia treatments has contributed to the rapid adoption of novel therapies. The increased diagnosis rates, patient awareness, and access to newer treatments like gene therapy and extended-acting clotting factors have significantly boosted the demand for hemophilia care in North America, solidifying its position as the largest market.

Key Regional Takeaways:

United States Hemophilia Market Analysis

In 2025, the United States accounted for 93.50% of the hemophilia market in North America, driven by multiple factors. United States is a significant contributor to this market share owing to the increase in specialized hemophilia treatment centers (HTCs) across the country. As per the National Bleeding Disorders Foundation, approximately 141 federally funded treatment centers and programs are active in the US. These centers are integral in delivering comprehensive care, improving early diagnosis, and enhancing patient outcomes. The rise in public and private sector funding has led to the expansion of HTCs, ensuring more widespread access to advanced treatments. With continued investments in healthcare infrastructure and specialized care models, adoption rates of hemophilia therapies are steadily increasing. The growing presence of HTCs, combined with strategic collaborations between healthcare providers and pharmaceutical companies, strengthens the market by offering patients more reliable diagnosis and treatment options. This development continues to foster greater patient engagement and boosts the overall growth of the market.

Asia Pacific Hemophilia Market Analysis

The Asia-Pacific region is experiencing a notable rise in hemophilia adoption, largely driven by the increasing prevalence of genetic disorders in the area. According to the Tata Institute for Genetics and Society, there are 5000-8000 rare genetic diseases identified globally, with 450 cases reported in India. Hemophilia, particularly its genetic transmission through inherited X-linked recessive mutations, plays a significant role in the increasing patient population. Public health initiatives focusing on early detection, genetic counseling, and awareness campaigns have improved the identification of hemophilia patients. Advances in diagnostic technologies further contribute to the quicker identification of genetic markers related to the disease. Additionally, better healthcare frameworks and government support are promoting the management of hemophilia across the region. These factors combined with the growing attention to rare genetic conditions create a positive environment for expanding hemophilia care and interventions in Asia-Pacific.

Europe Hemophilia Market Analysis

Europe's aging population is influencing the growing demand for specialized hemophilia care, as more individuals are living longer with the condition. By the beginning of 2024, Europe's population was estimated at 449.3 Million, with over 20% aged 65 or older. As life expectancy rises, patients diagnosed with hemophilia in their early years continue to require lifelong treatment, leading to an increased demand for healthcare resources. This demographic shift is placing greater focus on managing age-related complications in hemophilia, such as joint damage and associated comorbidities. Healthcare systems are adapting to this change by refining long-term therapy plans and mobility support services. The rise in geriatric patients with hemophilia is prompting healthcare providers to tailor treatment approaches to meet the needs of elderly patients, ensuring consistent access to replacement therapies and rehabilitation, driving the demand for specialized services in the region.

Latin America Hemophilia Market Analysis

In Latin America, the adoption of hemophilia treatments is on the rise due to the growing number of diagnosed cases in the region. Government data from Colombia in 2021 reported a prevalence of hemophilia A of 4.29 cases per 100,000 people. The increasing number of diagnoses, along with better access to healthcare services, is helping to raise awareness of the disease burden. Population screening programs have been instrumental in identifying more individuals affected by hemophilia, which in turn has heightened the demand for consistent and comprehensive treatment plans. As more patients are diagnosed and healthcare access improves, the need for ongoing therapy and specialized care is driving the market's expansion in Latin America.

Middle East and Africa Hemophilia Market Analysis

In the Middle East and Africa, hemophilia treatment adoption is rising as regional healthcare infrastructure continues to expand. The prevalence of hemophilia in countries across the Middle East and North Africa (MENA) region - such as Iraq, Iran, Turkey, Egypt, Jordan, Syria, and Saudi Arabia - ranges from 1.4 to 8.1 per 100,000 people. Strengthening healthcare systems and the introduction of new therapy and diagnostic centers are improving access to specialized services and early detection. Advances in diagnostic capabilities and treatment options have contributed to greater hemophilia care availability in underserved regions. As healthcare infrastructure continues to improve, more patients are gaining access to effective treatments, resulting in increased adoption of hemophilia care across the Middle East and Africa.

Competitive Landscape:

As per the hemophilia market forecast, leading companies in the market are focusing on R&D to develop advanced formulations with better efficacy and fewer side effects, reflecting the shift toward safer and more effective treatments. Expansions through acquisitions, partnerships, and global collaborations are driving the market, enabling companies to access new markets and technologies. Regulatory compliance and sustainable manufacturing remain key priorities, underscoring their commitment to quality, safety, and environmental responsibility.

The report provides a comprehensive analysis of the competitive landscape in the hemophilia market with detailed profiles of all major companies, including:

  • Baxter International Inc.
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • CSL Behring (CSL Limited)
  • F. Hoffmann-La Roche AG
  • Grifols S.A.
  • Kedrion S.p.A.
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Key Questions Answered in This Report

  • 1.How big is the hemophilia market?
  • 2.What is the future outlook of hemophilia market?
  • 3.What are the key factors driving the hemophilia market?
  • 4.Which region accounts for the largest hemophilia market share?
  • 5.Which are the leading companies in the global hemophilia market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hemophilia Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Hemophilia A
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Hemophilia B
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Hemophilia C
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Treatment

  • 7.1 On-Demand
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Prophylaxis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Therapy

  • 8.1 Replacement Therapy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 ITI Therapy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Gene Therapy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Baxter International Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bayer AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 BioMarin Pharmaceutical Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 CSL Behring (CSL Limited)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 F. Hoffmann-La Roche AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 Grifols S.A.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Kedrion S.p.A.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Novo Nordisk A/S
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Octapharma AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 SWOT Analysis
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Sanofi S.A.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Takeda Pharmaceutical Company Limited
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hemophilia Market: Sales Value (in Billion USD), 2020-2025
  • Figure 2: Global: Hemophilia Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 3: Global: Hemophilia Market: Breakup by Type (in %), 2025
  • Figure 4: Global: Hemophilia Market: Breakup by Treatment (in %), 2025
  • Figure 5: Global: Hemophilia Market: Breakup by Therapy (in %), 2025
  • Figure 6: Global: Hemophilia Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Hemophilia (Hemophilia A) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 8: Global: Hemophilia (Hemophilia A) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 9: Global: Hemophilia (Hemophilia B) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Hemophilia (Hemophilia B) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Hemophilia (Hemophilia C) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Hemophilia (Hemophilia C) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Hemophilia (Other Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Hemophilia (Other Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Hemophilia (On-Demand) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Hemophilia (On-Demand) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Hemophilia (Prophylaxis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Hemophilia (Prophylaxis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Hemophilia (Replacement Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Hemophilia (Replacement Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Hemophilia (ITI Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Hemophilia (ITI Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Hemophilia (Gene Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Hemophilia (Gene Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: North America: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: North America: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: United States: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: United States: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Canada: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Canada: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Asia-Pacific: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Asia-Pacific: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: China: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: China: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Japan: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Japan: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: India: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: India: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: South Korea: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: South Korea: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Australia: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Australia: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Indonesia: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Indonesia: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Others: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Others: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Europe: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Europe: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Germany: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Germany: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: France: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: France: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: United Kingdom: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: United Kingdom: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Italy: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Italy: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Spain: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Spain: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Russia: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Russia: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Others: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Others: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Latin America: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Latin America: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Brazil: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Brazil: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Mexico: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Mexico: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Others: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Others: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Middle East and Africa: Hemophilia Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Middle East and Africa: Hemophilia Market: Breakup by Country (in %), 2025
  • Figure 73: Middle East and Africa: Hemophilia Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Global: Hemophilia Industry: SWOT Analysis
  • Figure 75: Global: Hemophilia Industry: Value Chain Analysis
  • Figure 76: Global: Hemophilia Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hemophilia Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Hemophilia Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Hemophilia Market Forecast: Breakup by Treatment (in Million USD), 2026-2034
  • Table 4: Global: Hemophilia Market Forecast: Breakup by Therapy (in Million USD), 2026-2034
  • Table 5: Global: Hemophilia Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Hemophilia Market: Competitive Structure
  • Table 7: Global: Hemophilia Market: Key Players